JRCT ID: jRCT2080225337
Registered date:24/08/2020
Basic Information
Recruitment status | preinitiation |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 08/09/2020 |
Target sample size | 500 |
Countries of recruitment | Japan,North America,Europe,Oceania |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : spesolimab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | safety |
---|---|
Secondary Outcome | efficacy |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT04493424,JapicCTI-205433 |
Contact
Public contact | |
Name | |
Address | |
Telephone | +81-3-6417-2770 |
https://www.boehringer-ingelheim.jp/%E6%B2%BB%E9%A8%93%E3%81%AB%E9%96%A2%E3%81%99%E3%82%8B%E3%81%8A%E5%95%8F%E3%81%84%E5%90%88%E3%82%8F%E3%81%9B | |
Affiliation | |
Scientific contact | |
Name | |
Address | |
Telephone | +81-3-6417-2770 |
https://www.boehringer-ingelheim.jp/%E6%B2%BB%E9%A8%93%E3%81%AB%E9%96%A2%E3%81%99%E3%82%8B%E3%81%8A%E5%95%8F%E3%81%84%E5%90%88%E3%82%8F%E3%81%9B | |
Affiliation |